A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin+Paclitaxel or MPDL3280A In Combination with Carboplatin+ NAB-Pacilitaxel Versus Carboplatin+Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer

December 29, 2015

Type of Cancer

Lung

Site

Freehold, Sparta

Sponsor

Genentech

Protocol Number

GO29437

Staging

Phase of Trial

Protocol Title

A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call

(201)-510-0950